These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35809113)

  • 1. Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study).
    Royo-Cebrecos C; Robert-Montaner Ï; Vilanova D; Bailles E; Serrano-Pons J; Valero O; Buldon JM; Bermudez-de-Castro L; Mahia E; Pujadas J; Cobo F; Piqué JM; Albiol S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2883-2892. PubMed ID: 35809113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra.
    Royo-Cebrecos C; Vilanova D; López J; Arroyo V; Pons M; Francisco G; Carrasco MG; Piqué JM; Sanz S; Dobaño C; García-Basteiro AL
    Lancet Reg Health Eur; 2021 Jun; 5():100119. PubMed ID: 34557824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study.
    Meyers E; Deschepper E; Duysburgh E; De Rop L; De Burghgraeve T; Van Ngoc P; Digregorio M; Delogne S; Coen A; De Clercq N; Buret L; Coenen S; Sutter A; Scholtes B; Verbakel JY; Cools P; Heytens S
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.
    Erdoğan AP; Ekinci F; Akçalı S; Göksel G
    J Infect Chemother; 2022 Sep; 28(9):1310-1316. PubMed ID: 35701330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.
    Martins-Branco D; Nader-Marta G; Tecic Vuger A; Debien V; Ameye L; Brandão M; Punie K; Loizidou A; Willard-Gallo K; Spilleboudt C; Awada A; Piccart M; de Azambuja E
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3075-3080. PubMed ID: 35867203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
    Wong SY; Wellens J; Helmus D; Marlow L; Brann S; Martinez Pazos V; Weinberg A; Moran HR; McGregor C; Vermeire S; Watanabe K; Kamikozuru K; Ahuja V; Vermani S; Lindsay JO; Kingston A; Dutta U; Kaur H; Silverberg MS; Milgrom R; Chien Ng S; Mak JWY; Cadwell K; Thompson C; Colombel JF; Satsangi J;
    Inflamm Bowel Dis; 2023 Nov; 29(11):1693-1705. PubMed ID: 37354560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases.
    Poparn H; Srichumpuang C; Sosothikul D; Jantarabenjakul W; Lauhasurayotin S; Techavichit P; Chiangthong K; Poovorawan Y
    Asian Pac J Cancer Prev; 2022 Jun; 23(6):2049-2055. PubMed ID: 35763647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic.
    Javadinia SA; Ariamanesh M; Nabavifard M; Porouhan P; PeyroShabany B; Fazilat-Panah D; Hatami F; Ghasemi A; Lyman GH; Welsh JS; Ashkar Tizabi S; Dehghani M
    Cancer Invest; 2022 Feb; 40(2):115-123. PubMed ID: 34699294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
    Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
    Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
    Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA
    Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data.
    Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Oliveros-Acebes E; García-Navarro MJ; Khosravi-Shahi P
    Cancer Treat Rev; 2020 Nov; 90():102102. PubMed ID: 32947121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Newborn Dried Blood Spots to Ascertain Seroprevalence of SARS-CoV-2 Antibodies Among Individuals Giving Birth in New York State, November 2019 to November 2021.
    Damjanovic A; Styer LM; Nemeth K; Yauney E; Rock JM; Bievenue R; Hoen R; Ehrbar D; Kay DM; Caggana M; Parker MM
    JAMA Netw Open; 2022 Aug; 5(8):e2227995. PubMed ID: 35994287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign.
    Meyers E; De Rop L; Deschepper E; Duysburgh E; De Burghgraeve T; Van Ngoc P; Digregorio M; Delogne S; Coen A; De Clercq N; Buret L; Coenen S; De Sutter A; Scholtes B; Verbakel JY; Cools P; Heytens S
    Eur J Gen Pract; 2023 Dec; 29(2):2149732. PubMed ID: 36440533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.